The 2016 updated EULAR evidence-based recommendations for the management of gout aim to provide physicians with the best strategies for treating gout, including both non-pharmacological and pharmacological approaches. These recommendations are based on a systematic review of the literature and a Delphi consensus approach. The key principles include patient education, lifestyle modifications, and the importance of maintaining serum uric acid (SUA) levels below a target. For acute gout flares, colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, or a combination are recommended. In patients with frequent flares and contraindications to colchicine, NSAIDs, and corticosteroids, an interleukin-1 (IL-1) blocker should be considered. Urate-lowering therapy (ULT) should be considered from the first presentation of the disease, with SUA levels maintained at <6 mg/dL (360 μmol/L) and <5 mg/dL (300 μmol/L) in those with severe gout. Allopurinol is recommended as first-line ULT, with dosage adjusted according to renal function. If the SUA target cannot be achieved with allopurinol, febuxostat, a uricosuric, or a combination of a xanthine oxidase inhibitor and a uricosuric should be considered. For patients with refractory gout, pegloticase is recommended. The recommendations emphasize the importance of early initiation of ULT, especially in patients with comorbidities or high SUA levels. The task force also highlights the need for regular monitoring of SUA levels and adjusting ULT doses accordingly. Additionally, the recommendations include specific guidance on the use of ULTs in patients with renal impairment, with allopurinol dosage adjusted to creatinine clearance. The recommendations also address the use of IL-1 blockers in patients with contraindications to other treatments and the importance of lifestyle modifications, such as weight loss, avoiding alcohol and sugar-sweetened drinks, and encouraging low-fat dairy products. The task force also emphasizes the importance of screening for associated comorbidities and cardiovascular risk factors in patients with gout. Overall, the recommendations aim to improve the management of gout and achieve the predefined urate target to cure the disease.The 2016 updated EULAR evidence-based recommendations for the management of gout aim to provide physicians with the best strategies for treating gout, including both non-pharmacological and pharmacological approaches. These recommendations are based on a systematic review of the literature and a Delphi consensus approach. The key principles include patient education, lifestyle modifications, and the importance of maintaining serum uric acid (SUA) levels below a target. For acute gout flares, colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, or a combination are recommended. In patients with frequent flares and contraindications to colchicine, NSAIDs, and corticosteroids, an interleukin-1 (IL-1) blocker should be considered. Urate-lowering therapy (ULT) should be considered from the first presentation of the disease, with SUA levels maintained at <6 mg/dL (360 μmol/L) and <5 mg/dL (300 μmol/L) in those with severe gout. Allopurinol is recommended as first-line ULT, with dosage adjusted according to renal function. If the SUA target cannot be achieved with allopurinol, febuxostat, a uricosuric, or a combination of a xanthine oxidase inhibitor and a uricosuric should be considered. For patients with refractory gout, pegloticase is recommended. The recommendations emphasize the importance of early initiation of ULT, especially in patients with comorbidities or high SUA levels. The task force also highlights the need for regular monitoring of SUA levels and adjusting ULT doses accordingly. Additionally, the recommendations include specific guidance on the use of ULTs in patients with renal impairment, with allopurinol dosage adjusted to creatinine clearance. The recommendations also address the use of IL-1 blockers in patients with contraindications to other treatments and the importance of lifestyle modifications, such as weight loss, avoiding alcohol and sugar-sweetened drinks, and encouraging low-fat dairy products. The task force also emphasizes the importance of screening for associated comorbidities and cardiovascular risk factors in patients with gout. Overall, the recommendations aim to improve the management of gout and achieve the predefined urate target to cure the disease.